Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue Haupt

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Cancer Letters|June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinomaLan Cao, Ahmed Basudan, Matthew J Sikora, et al.
Breast Cancer Research : BCR|August 14, 2020
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancerNeil Portman, Heloisa H Milioli, Sarah Alexandrou, et al.
Science Signaling|January 12, 2017
Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancerCristina Gamell, Twishi Gulati, Yaara Levav-Cohen, et al.
Nature Communications|June 13, 2015
Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activitiesMadhusudhan Kollareddy, Elizabeth Dimitrova, Krishna C Vallabhaneni, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hotSimon P Keam, Heloise Halse, Thu Nguyen, et al.
The Journal of Pathology|January 19, 2017
MDM4 is a rational target for treating breast cancers with mutant p53Panimaya Jeffreena Miranda, Daniel Buckley, Dinesh Raghu, et al.
Cell Death & Disease|September 8, 2022
Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten lossJavier Octavio Mejía-Hernández, Simon P Keam, Reem Saleh, et al.
Nature Communications|March 29, 2017
Inhibiting the system x<sub>C</sub><sup>-</sup>/glutathione axis selectively targets cancers with mutant-p53 accumulationDavid S Liu, Cuong P Duong, Sue Haupt, et al.
Cancer Research|May 28, 2016
The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho SignalingMariam Mansour, Sue Haupt, Ai-Leen Chan, et al.
Nature Medicine|July 24, 2012
MDM4 is a key therapeutic target in cutaneous melanomaAgnieszka Gembarska, Flavie Luciani, Clare Fedele, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Cancer Letters|June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinomaLan Cao, Ahmed Basudan, Matthew J Sikora, et al.
Breast Cancer Research : BCR|August 14, 2020
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancerNeil Portman, Heloisa H Milioli, Sarah Alexandrou, et al.
Science Signaling|January 12, 2017
Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancerCristina Gamell, Twishi Gulati, Yaara Levav-Cohen, et al.
Nature Communications|June 13, 2015
Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activitiesMadhusudhan Kollareddy, Elizabeth Dimitrova, Krishna C Vallabhaneni, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hotSimon P Keam, Heloise Halse, Thu Nguyen, et al.
The Journal of Pathology|January 19, 2017
MDM4 is a rational target for treating breast cancers with mutant p53Panimaya Jeffreena Miranda, Daniel Buckley, Dinesh Raghu, et al.
Cell Death & Disease|September 8, 2022
Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten lossJavier Octavio Mejía-Hernández, Simon P Keam, Reem Saleh, et al.
Nature Communications|March 29, 2017
Inhibiting the system x<sub>C</sub><sup>-</sup>/glutathione axis selectively targets cancers with mutant-p53 accumulationDavid S Liu, Cuong P Duong, Sue Haupt, et al.
Cancer Research|May 28, 2016
The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho SignalingMariam Mansour, Sue Haupt, Ai-Leen Chan, et al.
Nature Medicine|July 24, 2012
MDM4 is a key therapeutic target in cutaneous melanomaAgnieszka Gembarska, Flavie Luciani, Clare Fedele, et al.
Pageof 6